Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model

Su Kyoung Jo, Bo Eun Ahn, Eun Hye Choi, Ji Eun Kang, Hyonggin An, Myoung don Oh, Gi eun Rhie

Research output: Contribution to journalArticle

Abstract

The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to A/J mice and the mice were subsequently challenged with 100 × LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.

Original languageEnglish
Pages (from-to)1586-1588
Number of pages3
JournalVaccine
Volume38
Issue number7
DOIs
StatePublished - 11 Feb 2020

Fingerprint

Passive Immunization
neutralization
immunization
toxins
Vaccines
animal models
vaccines
antigens
Antigens
Bacillus anthracis
assays
Serum
mice
Spores
spores
survival rate
Anthrax Vaccines
lethal dose 50
Lethal Dose 50
confidence interval

Keywords

  • Anthrax vaccine
  • Passive immunization
  • Survival rate
  • Toxin neutralization assay

Cite this

Jo, Su Kyoung ; Ahn, Bo Eun ; Choi, Eun Hye ; Kang, Ji Eun ; An, Hyonggin ; Oh, Myoung don ; Rhie, Gi eun. / Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model. In: Vaccine. 2020 ; Vol. 38, No. 7. pp. 1586-1588.
@article{494884087db647e8851532cd561bcc05,
title = "Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model",
abstract = "The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to A/J mice and the mice were subsequently challenged with 100 × LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50{\%} survival rate against lethal challenge was 197 (95{\%} confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.",
keywords = "Anthrax vaccine, Passive immunization, Survival rate, Toxin neutralization assay",
author = "Jo, {Su Kyoung} and Ahn, {Bo Eun} and Choi, {Eun Hye} and Kang, {Ji Eun} and Hyonggin An and Oh, {Myoung don} and Rhie, {Gi eun}",
year = "2020",
month = "2",
day = "11",
doi = "10.1016/j.vaccine.2019.12.048",
language = "English",
volume = "38",
pages = "1586--1588",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "7",

}

Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model. / Jo, Su Kyoung; Ahn, Bo Eun; Choi, Eun Hye; Kang, Ji Eun; An, Hyonggin; Oh, Myoung don; Rhie, Gi eun.

In: Vaccine, Vol. 38, No. 7, 11.02.2020, p. 1586-1588.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model

AU - Jo, Su Kyoung

AU - Ahn, Bo Eun

AU - Choi, Eun Hye

AU - Kang, Ji Eun

AU - An, Hyonggin

AU - Oh, Myoung don

AU - Rhie, Gi eun

PY - 2020/2/11

Y1 - 2020/2/11

N2 - The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to A/J mice and the mice were subsequently challenged with 100 × LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.

AB - The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to A/J mice and the mice were subsequently challenged with 100 × LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy.

KW - Anthrax vaccine

KW - Passive immunization

KW - Survival rate

KW - Toxin neutralization assay

UR - http://www.scopus.com/inward/record.url?scp=85077332719&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.12.048

DO - 10.1016/j.vaccine.2019.12.048

M3 - Article

AN - SCOPUS:85077332719

VL - 38

SP - 1586

EP - 1588

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -